Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person The transcriptional regulation of CD274 (PD-L1/programmed de...

Class:IdSummation:9912811
_displayNameThe transcriptional regulation of CD274 (PD-L1/programmed de...
_timestamp2024-06-10 12:28:44
created[InstanceEdit:9912800] Tiwari, Krishna, 2024-06-10
modified[InstanceEdit:9912831] Tiwari, Krishna, 2024-06-10
textThe transcriptional regulation of CD274 (PD-L1/programmed death-ligand 1) is crucial in cancer biology, enabling tumor cells to evade immune detection. PD-L1 expression is tightly controlled by various transcription factors and signalling pathways responding to both intrinsic cellular signals and extrinsic environmental perturbations. It is regulated transcriptionally by multiple mechanisms, including epigenetic modifications (EZH2, DNMTs, MLLs) and transcription factors (STAT3, STAT1, IRF1, MYC, HIF, and others) activated by various upstream signalling pathways. The regulation of PD-L1 is a complex interplay of oncogenic signalling pathways, cytokine responses, epigenetic modifications, specific transcription factors, the tumor microenvironment, and non-coding RNAs. This multifaceted regulation finely tunes PD-L1 expression to promote immune evasion in cancer, making it a critical target for cancer immunotherapy (Zhou et al., 2023, Cha et al.,2019, Yamaguchi et al.,2022, Ju et al., 2020).
(summation)[BlackBoxEvent:9909623] CD274 Transcription [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by The transcriptional regulation of CD274 (PD-L1/programmed de... (9912811)